Yoshihisa Tokumaru

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 35

Top Venues

Cancers

Breast cancer (Tokyo, Japan)

International journal of molecular sciences

Scientific reports

Roswell Park Comprehensive Cancer Center

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Roswell Park Comprehensive Cancer Center Apr 01 2019

United States

Post-doctoral :: Breast Surgery, Department of Surgical Oncology

Publications

Manabu Futamura, Kazuhiro Ishihara, Yasuko Nagao, Atsuko Ogiso, Yoshimi Niwa, Takumi Nakada, Yoshihiro Kawaguchi, Ai Ikawa, Iwao Kumazawa, Ryutaro Mori, Mai Kitazawa, Yoshiki Hosono, Masashi Kuno, Mana Kawajiri, Akira Nakakami, Makoto Takeuchi, Akemi Morikawa, Yoshihisa Tokumaru, Yasuo Katagiri, Yoshimasa Asano, Yoshinori Mushika, Toshio Shimokawa, Nobuhisa Matsuhasih
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04). Breast cancer (Tokyo, Japan) 30 (2) (2023)
Manabu Futamura, Kazuhiro Ishihara, Yasuko Nagao, Atsuko Ogiso, Yoshimi Niwa, Takumi Nakada, Yoshihiro Kawaguchi, Ai Ikawa, Iwao Kumazawa, Ryutaro Mori, Mai Kitazawa, Yoshiki Hosono, Masashi Kuno, Mana Kawajiri, Akira Nakakami, Makoto Takeuchi, Akemi Morikawa, Yoshihisa Tokumaru, Yasuo Katagiri, Yoshimasa Asano, Yoshinori Mushika, Toshio Shimokawa, Nobuhisa Matsuhasih
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04). Breast cancer (Tokyo, Japan) 30 (2) (2023)
Manabu Futamura, Kazuhiro Ishihara, Yasuko Nagao, Atsuko Ogiso, Yoshimi Niwa, Takumi Nakada, Yoshihiro Kawaguchi, Ai Ikawa, Iwao Kumazawa, Ryutaro Mori, Mai Kitazawa, Yoshiki Hosono, Masashi Kuno, Mana Kawajiri, Akira Nakakami, Makoto Takeuchi, Akemi Morikawa, Yoshihisa Tokumaru, Yasuo Katagiri, Yoshimasa Asano, Yoshinori Mushika, Toshio Shimokawa, Nobuhisa Matsuhasih
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04). Breast cancer (Tokyo, Japan) (2023)
Manabu Futamura, Takahiro Nakayama, Tetsuhiro Yoshinami, Chiya Oshiro, Mikiya Ishihara, Midori Morita, Akira Watanabe, Azusa Tanigichi, Masami Tsukabe, Masafumi Shimoda, Kanae Nitta, Yoko Chihara, Hiroyuki Yasojima, Yoshimi Ouchi, Yoshihisa Tokumaru, Norikazu Masuda
Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316). Breast cancer (Tokyo, Japan) (2023)
Manabu Futamura, Kazuhiro Ishihara, Yasuko Nagao, Atsuko Ogiso, Yoshimi Niwa, Takumi Nakada, Yoshihiro Kawaguchi, Ai Ikawa, Iwao Kumazawa, Ryutaro Mori, Mai Kitazawa, Yoshiki Hosono, Masashi Kuno, Mana Kawajiri, Akira Nakakami, Makoto Takeuchi, Akemi Morikawa, Yoshihisa Tokumaru, Yasuo Katagiri, Yoshimasa Asano, Yoshinori Mushika, Toshio Shimokawa, Nobuhisa Matsuhasih
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04). Breast cancer (Tokyo, Japan) 30 (2) (2023)
Manabu Futamura, Kazuhiro Ishihara, Yasuko Nagao, Atsuko Ogiso, Yoshimi Niwa, Takumi Nakada, Yoshihiro Kawaguchi, Ai Ikawa, Iwao Kumazawa, Ryutaro Mori, Mai Kitazawa, Yoshiki Hosono, Masashi Kuno, Mana Kawajiri, Akira Nakakami, Makoto Takeuchi, Akemi Morikawa, Yoshihisa Tokumaru, Yasuo Katagiri, Yoshimasa Asano, Yoshinori Mushika, Toshio Shimokawa, Nobuhisa Matsuhasih
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04). Breast cancer (Tokyo, Japan) 30 (2) (2023)
Manabu Futamura, Kazuhiro Ishihara, Yasuko Nagao, Atsuko Ogiso, Yoshimi Niwa, Takumi Nakada, Yoshihiro Kawaguchi, Ai Ikawa, Iwao Kumazawa, Ryutaro Mori, Mai Kitazawa, Yoshiki Hosono, Masashi Kuno, Mana Kawajiri, Akira Nakakami, Makoto Takeuchi, Akemi Morikawa, Yoshihisa Tokumaru, Yasuo Katagiri, Yoshimasa Asano, Yoshinori Mushika, Toshio Shimokawa, Nobuhisa Matsuhasih
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04). Breast cancer (Tokyo, Japan) 30 (2) (2023)
Rongrong Wu, Arya Mariam Roy, Yoshihisa Tokumaru, Shipra Gandhi, Mariko Asaoka, Masanori Oshi, Li Yan, Takashi Ishikawa, Kazuaki Takabe
NR2F1, a Tumor Dormancy Marker, Is Expressed Predominantly in Cancer-Associated Fibroblasts and Is Associated with Suppressed Breast Cancer Cell Proliferation. Cancers 14 (12) (2022)
Irene Yu, Rongrong Wu, Yoshihisa Tokumaru, Krista P Terracina, Kazuaki Takabe
The Role of the Microbiome on the Pathogenesis and Treatment of Colorectal Cancer. Cancers 14 (22) (2022)
Masanori Oshi, Yoshihisa Tokumaru, Fernando A Angarita, Lan Lee, Li Yan, Ryusei Matsuyama, Itaru Endo, Kazuaki Takabe
Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival. Scientific reports 11 (1) (2021)
Yoshihisa Tokumaru, Masanori Oshi, Michelle R Huyser, Li Yan, Masahiro Fukada, Nobuhisa Matsuhashi, Manabu Futamura, Yukihiro Akao, Kazuhiro Yoshida, Kazuaki Takabe
Low expression of miR-29a is associated with aggressive biology and worse survival in gastric cancer. Scientific reports 11 (1) (2021)
Masanori Oshi, Vijayashree Murthy, Hideo Takahashi, Michelle Huyser, Maiko Okano, Yoshihisa Tokumaru, Omar M Rashid, Ryusei Matsuyama, Itaru Endo, Kazuaki Takabe
Urine as a Source of Liquid Biopsy for Cancer. Cancers 13 (11) (2021)
Masanori Oshi, Fernando A Angarita, Yoshihisa Tokumaru, Li Yan, Ryusei Matsuyama, Itaru Endo, Kazuaki Takabe
A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Cancers 13 (10) (2021)
Yoshihisa Tokumaru, Masanori Oshi, Ankit Patel, Wanqing Tian, Li Yan, Nobuhisa Matsuhashi, Manabu Futamura, Kazuhiro Yoshida, Kazuaki Takabe
Organoids Are Limited in Modeling the Colon Adenoma-Carcinoma Sequence. Cells 10 (3) (2021)
Vijayashree Murthy, Jessica Young, Yoshihisa Tokumaru, Marie Quinn, Stephen B Edge, Kazuaki Takabe
Options to Determine Pathological Response of Axillary Lymph Node Metastasis after Neoadjuvant Chemotherapy in Advanced Breast Cancer. Cancers 13 (16) (2021)
Masanori Oshi, Yoshihisa Tokumaru, Swagoto Mukhopadhyay, Li Yan, Ryusei Matsuyama, Itaru Endo, Kazuaki Takabe
Annexin A1 Expression Is Associated with Epithelial-Mesenchymal Transition (EMT), Cell Proliferation, Prognosis, and Drug Response in Pancreatic Cancer. Cells 10 (3) (2021)
Masanori Oshi, Michelle R Huyser, Lan Le, Yoshihisa Tokumaru, Li Yan, Ryusei Matsuyama, Itaru Endo, Kazuaki Takabe
Abundance of Microvascular Endothelial Cells Is Associated with Response to Chemotherapy and Prognosis in Colorectal Cancer. Cancers 13 (6) (2021)
Masanori Oshi, Tae Hee Kim, Yoshihisa Tokumaru, Li Yan, Ryusei Matsuyama, Itraru Endo, Leonid Cherkassky, Kazuaki Takabe
Enhanced DNA Repair Pathway is Associated with Cell Proliferation and Worse Survival in Hepatocellular Carcinoma (HCC). Cancers 13 (2) (2021)
Masanori Oshi, Yoshihisa Tokumaru, Fernando A Angarita, Li Yan, Ryusei Matsuyama, Itaru Endo, Kazuaki Takabe
Degree of Early Estrogen Response Predict Survival after Endocrine Therapy in Primary and Metastatic ER-Positive Breast Cancer. Cancers 12 (12) (2020)
Yoshihisa Tokumaru, Mariko Asaoka, Masanori Oshi, Eriko Katsuta, Li Yan, Sumana Narayanan, Nobuhiko Sugito, Nobuhisa Matsuhashi, Manabu Futamura, Yukihiro Akao, Kazuhiro Yoshida, Kazuaki Takabe
High Expression of microRNA-143 is Associated with Favorable Tumor Immune Microenvironment and Better Survival in Estrogen Receptor Positive Breast Cancer. International journal of molecular sciences 21 (9) (2020)
Yoshihisa Tokumaru, Eriko Katsuta, Masanori Oshi, Judith C Sporn, Li Yan, Lan Le, Nobuhisa Matsuhashi, Manabu Futamura, Yukihiro Akao, Kazuhiro Yoshida, Kazuaki Takabe
High Expression of miR-34a Associated with Less Aggressive Cancer Biology but Not with Survival in Breast Cancer. International journal of molecular sciences 21 (9) (2020)
Masanori Oshi, Yoshihisa Tokumaru, Mariko Asaoka, Li Yan, Vikas Satyananda, Ryusei Matsuyama, Nobuhisa Matsuhashi, Manabu Futamura, Takashi Ishikawa, Kazuhiro Yoshida, Itaru Endo, Kazuaki Takabe
M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer. Scientific reports 10 (1) (2020)
Masanori Oshi, Hideo Takahashi, Yoshihisa Tokumaru, Li Yan, Omar M Rashid, Ryusei Matsuyama, Itaru Endo, Kazuaki Takabe
G2M Cell Cycle Pathway Score as a Prognostic Biomarker of Metastasis in Estrogen Receptor (ER)-Positive Breast Cancer. International journal of molecular sciences 21 (8) (2020)
Masanori Oshi, Stephanie Newman, Yoshihisa Tokumaru, Li Yan, Ryusei Matsuyama, Pawel Kalinski, Itaru Endo, Kazuaki Takabe
Plasmacytoid Dendritic Cell (pDC) Infiltration Correlate with Tumor Infiltrating Lymphocytes, Cancer Immunity, and Better Survival in Triple Negative Breast Cancer (TNBC) More Strongly than Conventional Dendritic Cell (cDC). Cancers 12 (11) (2020)
Yoshihisa Tokumaru, Masanori Oshi, Eriko Katsuta, Li Yan, Jing Li Huang, Masayuki Nagahashi, Nobuhisa Matsuhashi, Manabu Futamura, Kazuhiro Yoshida, Kazuaki Takabe
Intratumoral Adipocyte-High Breast Cancer Enrich for Metastatic and Inflammation-Related Pathways but Associated with Less Cancer Cell Proliferation. International journal of molecular sciences 21 (16) (2020)
Hideo Takahashi, Eriko Katsuta, Li Yan, Yoshihisa Tokumaru, Matthew H G Katz, Kazuaki Takabe
Transcriptomic Profile of Lymphovascular Invasion, a Known Risk Factor of Pancreatic Ductal Adenocarcinoma Metastasis. Cancers 12 (8) (2020)
Yoshihisa Tokumaru, Kazuaki Takabe, Kazuhiro Yoshida, Yukihiro Akao
Effects of MIR143 on rat sarcoma signaling networks in solid tumors: A brief overview. Cancer science 111 (4) (2020)
Masanori Oshi, Fernando A Angarita, Yoshihisa Tokumaru, Li Yan, Ryusei Matsuyama, Itaru Endo, Kazuaki Takabe
High Expression of NRF2 Is Associated with Increased Tumor-Infiltrating Lymphocytes and Cancer Immunity in ER-Positive/HER2-Negative Breast Cancer. Cancers 12 (12) (2020)
Masanori Oshi, Yoshihisa Tokumaru, Ankit Patel, Li Yan, Ryusei Matsuyama, Itaru Endo, Matthew H G Katz, Kazuaki Takabe
A Novel Four-Gene Score to Predict Pathologically Complete (R0) Resection and Survival in Pancreatic Cancer. Cancers 12 (12) (2020)
Masanori Oshi, Stephanie Newman, Vijayashree Murthy, Yoshihisa Tokumaru, Li Yan, Ryusei Matsuyama, Itaru Endo, Kazuaki Takabe
ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer. Cancers 12 (10) (2020)
Masanori Oshi, Stephanie Newman, Yoshihisa Tokumaru, Li Yan, Ryusei Matsuyama, Itaru Endo, Kazuaki Takabe
Inflammation Is Associated with Worse Outcome in the Whole Cohort but with Better Outcome in Triple-Negative Subtype of Breast Cancer Patients. Journal of immunology research 2020 (2020)
Masanori Oshi, Stephanie Newman, Yoshihisa Tokumaru, Li Yan, Ryusei Matsuyama, Itaru Endo, Masayuki Nagahashi, Kazuaki Takabe
Intra-Tumoral Angiogenesis Is Associated with Inflammation, Immune Reaction and Metastatic Recurrence in Breast Cancer. International journal of molecular sciences 21 (18) (2020)
Masanori Oshi, Mariko Asaoka, Yoshihisa Tokumaru, Li Yan, Ryusei Matsuyama, Takashi Ishikawa, Itaru Endo, Kazuaki Takabe
CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer. International journal of molecular sciences 21 (18) (2020)
Masanori Oshi, Mariko Asaoka, Yoshihisa Tokumaru, Fernando A Angarita, Li Yan, Ryusei Matsuyama, Emese Zsiros, Takashi Ishikawa, Itaru Endo, Kazuaki Takabe
Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Cancers 12 (10) (2020)
Yoshihisa Tokumaru, Toshihiro Tajirika, Nobuhiko Sugito, Yuki Kuranaga, Haruka Shinohara, Takuya Tsujino, Nobuhisa Matsuhashi, Manabu Futamura, Yukihiro Akao, Kazuhiro Yoshida
Synthetic miR-143 Inhibits Growth of HER2-Positive Gastric Cancer Cells by Suppressing KRAS Networks Including DDX6 RNA Helicase. International journal of molecular sciences 20 (7) (2019)

Yoshihisa Tokumaru.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yoshihisa Tokumaru